iTeos Therapeutics (NASDAQ:ITOS) vs. Invizyne Technologies (NASDAQ:IZTC) Head-To-Head Analysis

iTeos Therapeutics (NASDAQ:ITOS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Earnings and Valuation

This table compares iTeos Therapeutics and Invizyne Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$35.00 million	7.10	-$112.64 million	($3.31)	-1.97
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has lower revenue, but higher earnings than iTeos Therapeutics.

Institutional & Insider Ownership

97.2% of iTeos Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for iTeos Therapeutics and Invizyne Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	4	0	3.00
Invizyne Technologies	0	0	0	0	0.00

iTeos Therapeutics presently has a consensus target price of $25.75, indicating a potential upside of 295.55%. Given iTeos Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe iTeos Therapeutics is more favorable than Invizyne Technologies.

Profitability

This table compares iTeos Therapeutics and Invizyne Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-20.11%	-17.50%
Invizyne Technologies	N/A	N/A	N/A

Summary

iTeos Therapeutics beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.